- Home
- CR vs ARWR Comparison
CR vs ARWR Comparison
Compare CR & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CR | ARWR |
|---|---|---|
| Founded | 1855 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.7B | 9.3B |
| IPO Year | 2022 | 2009 |
Fundamental Metrics
Financial Performance| Metric | CR | ARWR |
|---|---|---|
| Price | $180.31 | $73.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | ★ $226.20 | $83.40 |
| AVG Volume (30 Days) | 496.9K | ★ 1.6M |
| Earning Date | 04-27-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.58% | N/A |
| EPS Growth | 23.96 | ★ 99.80 |
| EPS | ★ 1.14 | N/A |
| Revenue | ★ $2,305,000,000.00 | $16,142,321.00 |
| Revenue This Year | $27.98 | N/A |
| Revenue Next Year | $5.76 | N/A |
| P/E Ratio | ★ $158.75 | $353.91 |
| Revenue Growth | ★ 8.16 | N/A |
| 52 Week Low | $159.58 | $14.30 |
| 52 Week High | $214.31 | $79.48 |
Technical Indicators
Market Signals| Indicator | CR | ARWR |
|---|---|---|
| Relative Strength Index (RSI) | 49.78 | 54.91 |
| Support Level | $177.86 | $60.60 |
| Resistance Level | $185.01 | $76.45 |
| Average True Range (ATR) | 6.91 | 3.58 |
| MACD | -0.02 | 0.04 |
| Stochastic Oscillator | 41.04 | 40.58 |
Price Performance
Historical ComparisonAbout CR Crane Company
Crane is a diversified industrial firm that manufactures a broad range of products, including valves, pumps, aerospace components, and fiberglass-reinforced plastic panels. Its business is organized into two segments: aerospace and advanced technologies, and process flow technologies. Crane generated approximately $2.3 billion in revenue in 2025.
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.